Synergistic effect of cilostazol and dipyridamole mediated by adenosine on shear-induced platelet aggregation

Thrombosis Research

Volumn 119, Issue 4, 2007, Pages 511-516

  Nakamura, Tomomi ^a   Uchiyama, Shinichiro ^a   Yamazaki, Masako ^a   Iwata, Makoto ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Adenosine; Cilostazol; Dipyridamole; Shear induced platelet aggregation

Indexed keywords

ADENOSINE; ADENOSINE DEAMINASE; CILOSTAZOL; DIPYRIDAMOLE;

ADULT; ARTICLE; BLOOD; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; IN VITRO STUDY; MALE; PRIORITY JOURNAL; SHEAR RATE; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

ADENOSINE; ADULT; DIPYRIDAMOLE; DRUG SYNERGISM; HUMANS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SHEAR STRENGTH; TETRAZOLES;

EID: 33846407224     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.05.005     Document Type: Article

References (34)

1. Goto F., Tohgi H., Hirai S., Terashi A., Fukuuchi Y., Otomo E., et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 9 (2000) 147-157
2. Umekawa H., Tanaka T., Kimura Y., and Hidaka H. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography. Biochem Pharmacol 33 (1984) 3339-3344
3. Kimura Y., Tani T., Kanbe T., and Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35 (1985) 1144-1149
4. Tanaka T., Ishikawa T., Hagiwara M., Onoda K., Itoh H., and Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor, on the contraction of vascular smooth muscle. Pharmacology 36 (1988) 313-320
5. Ikeda Y. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. Thromb Haemost 82 (1999) 435-438
6. Sun B., Le S.N., Lin S., Fong M., Guertin M., Liu Y., et al. New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation. J Cardiovasc Pharmacol 40 (2002) 577-585
7. Shryock J.C., and Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol 79 (1997) 2A-10A
8. Haslam R.J., and Rosson G.M. Effects of adenosine on levels of adenosine cyclic 3′,5′-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Mol Pharmacol 11 (1975) 528-544
9. Collis M.G., and Hourani S.M.O. Adenosine receptor subtypes. Trends Pharmacol Sci 14 (1993) 360-366
10. Strony J., Beaudoin A., Brands D., and Adelman B. Analysis of shear stress and hemodynamic factors in a model of coronary artery stenosis and thrombosis. Am J Physiol 265 (1993) H1787-H1796
11. Uchiyama S., Yamazaki M., Maruyama S., Handa M., Ikeda Y., Fukuyama M., et al. Shear-induced platelet aggregation and its inhibition by antiplatelet agents in cerebral ischemia. Clin Hemorheol 13 (1993) 623-636
12. Uchiyama S., Yamazaki M., Maruyama S., Handa M., Ikeda Y., Fukuyama M., et al. Shear-induced platelet aggregation in cerebral ischemia. Stroke 25 (1994) 1547-1551
13. Minami N., Suzuki Y., Yamamoto M., Kihira H., Imai E., Wada H., et al. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci 61 (1997) 383-389
14. Tanigawa T., Nishikawa M., Kitai T., Ueda Y., Okinaka T., Makino K., et al. Increased platelet aggregation in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. Am J Cardiol 85 (2000) 1054-1059
15. Gresele P., Zoja C., Deckmyn H., Arnout J., Vermylen J., and Verstraete M. Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemost 50 (1983) 852-856
16. Edlund A., Siden A., and Sollevi A. Evidence for an antiaggregatory effect of adenosine at physiological concentrations and its role in the action of dipyridamole. Thromb Res 45 (1987) 183-190
17. Woo S.K., Kang W.K., and Kwon K.I. Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans. Clin Pharmacol Ther 71 (2002) 246-252
18. Liu Y., Cone J., Le S.N., Fong M., Tao L., Shoaf S.E., et al. Cilostazol and dipyridamole synergistically inhibit human platelet aggregation. J Cardiovasc Pharmacol 44 (2004) 266-273
19. Agarwal K.C. Modulation of platelet functions by plasma adenosine. In: Imai S., and Nakazawa M. (Eds). Role of adenosine and adenine nucleotides in the biologic system (1991), Elsevier Science Publishers, Amsterdam 273-288
20. Anfossi G., Massucco P., Piretto V., Mularoni E., Cavalot F., Mattiello L., et al. Interplay between milrinone and adenosine in the inhibition of human platelet response. Gen Pharmacol 27 (1996) 1149-1154
21. Azuma H., Takashima Y., Ishikawa M., and Yamakado T. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (Oxagrelate), in human platelets in vitro. Jpn J Pharmacol 34 (1984) 159-170
22. Agarwal K.C., Buckley R.S., and Parks Jr. R.E. Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences. Thromb Res 47 (1987) 191-200
23. Liu Y., Fong M., Cone J., Wang S., Yoshitake M., and Kambayashi J. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol 36 (2000) 351-360
24. Liu Y., Shakur Y., Yoshitake M., and Kambayashi J. Cilostazol (Pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 19 (2001) 369-386
25. Moake J.L., Turner N.A., Stathopoulos N.A., Nolasco L., and Hellums J.D. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 71 (1988) 1366-1374
26. Ikeda Y., Handa M., Kawano K., Kamata T., Murata M., Araki Y., et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 87 (1991) 1234-1240
27. Wang S., Cone J., Fong M., Yoshitake M., Kambayashi J., and Liu Y. Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol 38 (2001) 775-783
28. Rosado J.A., Porras T., Conde M., and Sage S.O. Cyclic nucleotides modulate store-mediated calcium entry through the activation of protein-tyrosine phosphatases and altered actin polymerization in human platelets. J Biol Chem 276 (2001) 15666-15675
29. Soderback U., Sollevi A., Wallen N.H., Larsson P.T., and Hjemdahl P. Antiaggregatory effects of physiological concentrations of adenosine in human whole blood as assessed by filtragometry. Clin Sci 81 (1991) 691-696
30. Müller T.H., Su C.A.P.F., Weisenberger H., Brickl R., Nehmiz G., and Eisert W.G. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol 30 (1990) 179-186
31. Nakamura T., Uchiyama S., Yamazaki M., and Iwata M. Effects of dipyridamole and aspirin on shear induced platelet aggregation. Cerebrovasc Dis 22 (2002) 343-347
32. Dawicki D.D., Agarwal K.C., and Parks Jr. R.E. Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233. Thromb Res 43 (1986) 161-175
33. Bult H., Fret H.R.L., Jordaens F.H., and Herman A.G. Dipyridamole potentiates the anti-aggregating and vasodilator activity of nitric oxide. Eur J Pharmacol 199 (1991) 1-8
34. Nomura S., Inami N., Iwasaka T., and Liu Y. Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole. Platelets 15 (2004) 167-172